Bigfoot Biomedical announced the closing of its Series C financing round for a total of $55M. With the closing of Series C, the company says it is moving closer to FDA submission of Bigfoot Unity in 2020. Recall, Bigfoot Unity is a decision support system that leverages a connected insulin pen cap and the Abbott Libre CGM. Additionally, Bigfoot’s co-founder Bryan Mazlish (view LinkedIn profile) is transitioning from president of the company to the Executive Board Director. Below, FENIX provides insights into Bigfoot’s financing, management changes, and valuation and thoughts on how the Series C closing could potentially indicate Libre 2 FDA approval is imminent.